2018 American Transplant Congress
Use of HCV Ab+/NAT- Donors in HCV Naïve Renal Transplant Recipients
1Univeristy of Cincinnati Medical Center, Cincinnati, OH; 2The Christ Hospital, Cincinnati, OH.
The continued organ shortage in renal transplantation (RT) has stimulated use of organs from increased-risk donors to expand the donor pool. The rate of denovo…2018 American Transplant Congress
Clinical Outcomes of Kidney Transplant Recipients Infected with Hepatitis C Virus and Treated with Direct-Acting Antiviral Therapy
Introduction:Hepatitis C virus (HCV) infection has negative impact on patient and graft survival in kidney transplant recipients. In the past, treatment of HCV infection post…2018 American Transplant Congress
Disparity in Access to Kidney Allograft Offers among HIV+ Transplant Candidates
Background: Despite having a demonstrated survival benefit with kidney transplantation, patients with chronic viral infections, such as HCV or HIV, face many barriers to transplantation,…2018 American Transplant Congress
Timing of Treatment for Chronic Hepatitis C Infection in Patients with End-Stage Renal Disease Awaiting Transplantation
BackgroundIt is unclear whether patients with chronic hepatitis C virus (HCV) infection and end-stage renal disease (ESRD) should be treated for HCV before transplant or…2018 American Transplant Congress
Clinical and Pathological Findings in Hepatitis C Positive Renal Transplant Recipients Following Alemtuzumab Induction
University of Maryland Medical Center, Baltimore.
BackgroundHistorically, renal transplant recipients (RTRs) with chronic hepatitis C (HCV) have worse long-term outcomes. Induction with alemtuzumab (ALM) in HCV positive RTRs has been postulated…2018 American Transplant Congress
Excellent Outcomes for HCV-Viremic Recipients of Simultaneous Liver-Kidney Transplant in the Direct Anti-Viral Era
Piedmont Transplant Institute, Piedmont Healthcare, Atlanta, GA.
Before the era of direct anti-viral agents (DAAs), outcomes for HCV-viremic recipients of simultaneous liver kidney transplant (SLKT) were inferior to HCV-negative recipients. PURPOSE: To…2017 American Transplant Congress
Does Cirrhosis Regress in HCV Liver Transplant Recipients Achieving Sustained Virologic Response in the Era of Direct-Acting Antiviral Agents?
Background: Treatment with direct-acting antiviral agents (DAAs) in HCV patients is associated with high sustained virologic response (SVR) rates. It is hoped that cirrhosis regresses…2017 American Transplant Congress
Hepatitis C Genotypes Among Deceased Organ Donors in the United States.
1University of Pennsylvania, Philadelphia, PA; 2Gift of Life, Philadelphia, PA
Background: HCV is one of the leading causes of liver disease in the US. 5% of deceased organ donors are HCV+ and HCV infection is…2017 American Transplant Congress
Deceased Donors with a History of IV Drug Use and Donor Derived Hepatitis C Virus.
1OPTN Ad Hoc Disease Transmission Advisory Committee, Richmond, VA; 2UNOS, Richmond
Introduction:In 2015, the CDC reported a 172% increase in heroin-related deaths from 2010 to 2013. Deceased donors with IV drug use (IVDU) are at increased…2017 American Transplant Congress
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
Indiana University Health, Indianapolis
Background: Chronic Hepatitis C Virus (HCV) infection has a negative impact on graft survival. Prior treatments were poorly tolerated and had minimal cure rates. The…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 28
- Next Page »